Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $407,316 | 2 | 99.6% |
| Travel and Lodging | $1,184 | 3 | 0.3% |
| Food and Beverage | $461.87 | 10 | 0.1% |
| Education | $29.99 | 1 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $407,316 | 2 | $0 (2024) |
| ModernaTX, Inc. | $1,490 | 8 | $0 (2024) |
| Organon LLC | $69.38 | 2 | $0 (2022) |
| GlaxoSmithKline, LLC. | $44.73 | 2 | $0 (2017) |
| Boston Scientific Corporation | $41.76 | 1 | $0 (2023) |
| Allergan Inc. | $29.99 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $408,806 | 10 | Eli Lilly and Company ($407,316) |
| 2023 | $41.76 | 1 | Boston Scientific Corporation ($41.76) |
| 2022 | $69.38 | 2 | Organon LLC ($69.38) |
| 2018 | $29.99 | 1 | Allergan Inc. ($29.99) |
| 2017 | $44.73 | 2 | GlaxoSmithKline, LLC. ($44.73) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $531.06 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $412.95 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $240.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $120.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $81.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $45.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 09/10/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $404,818.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | ||||||
| 06/04/2024 | Eli Lilly and Company | — | — | In-kind items and services | $2,498.22 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | ||||||
| 09/29/2023 | Boston Scientific Corporation | WaveWriter Alpha Prime 16 (Device) | Food and Beverage | In-kind items and services | $41.76 | General |
| Category: WaveWriter Alpha_NMD | ||||||
| 02/16/2022 | Organon LLC | NEXPLANON (Drug) | Food and Beverage | In-kind items and services | $34.69 | General |
| Category: ETONOGESTREL | ||||||
| 02/16/2022 | Organon LLC | NEXPLANON (Drug) | Food and Beverage | In-kind items and services | $34.69 | General |
| Category: ETONOGESTREL | ||||||
| 03/07/2018 | Allergan Inc. | VRAYLAR (Drug) | Education | In-kind items and services | $29.99 | General |
| Category: NEUROSCIENCE | ||||||
| 12/13/2017 | GlaxoSmithKline, LLC. | FLULAVAL (Biological), SHINGRIX | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: VACCINES | ||||||
| 11/17/2017 | GlaxoSmithKline, LLC. | FLUARIX (Biological), FLULAVAL, SHINGRIX | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: VACCINES | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $407,316 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 949 | 1,666 | $314,010 | $82,292 |
| 2022 | 34 | 2,399 | 4,186 | $486,416 | $207,745 |
| 2021 | 36 | 2,297 | 4,099 | $350,995 | $179,350 |
| 2020 | 36 | 3,091 | 5,326 | $450,042 | $176,473 |
All Medicare Procedures & Services
126 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 348 | 748 | $168,900 | $56,849 | 33.7% |
| 99285 | Emergency department visit with high level of medical decision making | Facility | 2023 | 46 | 46 | $78,838 | $5,963 | 7.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 70 | 81 | $13,485 | $4,953 | 36.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 27 | 27 | $4,590 | $3,298 | 71.8% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 45 | 45 | $2,475 | $2,426 | 98.0% |
| 99284 | Emergency department visit with moderate level of medical decision making | Facility | 2023 | 26 | 26 | $28,183 | $2,327 | 8.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 60 | 152 | $5,784 | $1,442 | 24.9% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 23 | 24 | $1,800 | $1,399 | 77.7% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 20 | 20 | $1,726 | $1,192 | 69.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 47 | 47 | $940.00 | $921.20 | 98.0% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 18 | 18 | $451.00 | $311.58 | 69.1% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 29 | 30 | $796.00 | $285.60 | 35.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 29 | 31 | $350.00 | $260.40 | 74.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 16 | 17 | $463.00 | $175.95 | 38.0% |
| 81002 | Urinalysis, manual test | Office | 2023 | 33 | 42 | $294.00 | $143.22 | 48.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 18 | 18 | $388.00 | $136.98 | 35.3% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 20 | 22 | $2,266 | $123.80 | 5.5% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 11 | 45 | $900.00 | $51.26 | 5.7% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 31 | 188 | $900.00 | $16.66 | 1.9% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2023 | 32 | 39 | $481.00 | $15.67 | 3.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 581 | 1,547 | $303,840 | $127,671 | 42.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 209 | 310 | $38,970 | $18,002 | 46.2% |
| 90670 | Pneumococcal vaccine, 13-valent | Office | 2022 | 28 | 28 | $7,000 | $6,822 | 97.5% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 118 | 118 | $6,490 | $6,366 | 98.1% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2022 | 35 | 35 | $5,856 | $5,791 | 98.9% |
About Dr. Patrick Morgante, DO
Dr. Patrick Morgante, DO is a Family Medicine healthcare provider based in Havelock, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1881655371.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Morgante, DO has received a total of $408,992 in payments from pharmaceutical and medical device companies, with $408,806 received in 2024. These payments were reported across 16 transactions from 6 companies. The most common payment nature is "" ($407,316).
As a Medicare-enrolled provider, Morgante has provided services to 8,736 Medicare beneficiaries, totaling 15,277 services with total Medicare billing of $645,860. Data is available for 4 years (2020–2023), covering 126 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Havelock, NC
- Active Since 04/01/2006
- Last Updated 11/20/2023
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1881655371
Products in Payments
- NEXPLANON (Drug) $69.38
- WaveWriter Alpha Prime 16 (Device) $41.76
- VRAYLAR (Drug) $29.99
- FLULAVAL (Biological) $23.83
- FLUARIX (Biological) $20.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Havelock
Dr. William Crawford, Md, MD
Family Medicine — Payments: $790.61
Dr. Eugene Wilson, M.d, M.D
Family Medicine — Payments: $318.72
Simon O'regan, M.d, M.D
Family Medicine — Payments: $253.11
Rachel Concepcion, Do, DO
Family Medicine — Payments: $184.48
Samuel Ward, Do, DO
Family Medicine — Payments: $18.07
Cameron Brassfield, Do, DO
Family Medicine